[HTML][HTML] Cancer health disparities in racial/ethnic minorities in the United States
VA Zavala, PM Bracci, JM Carethers… - British journal of …, 2021 - nature.com
There are well-established disparities in cancer incidence and outcomes by race/ethnicity
that result from the interplay between structural, socioeconomic, socio-environmental …
that result from the interplay between structural, socioeconomic, socio-environmental …
[HTML][HTML] Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC
X Le, M Nilsson, J Goldman, M Reck… - Journal of Thoracic …, 2021 - Elsevier
The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 in: Journal of the
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …
National Comprehensive Cancer Network Volume 19 Issue 3 (2021) Jump to Content User …
NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines
DS Ettinger, DE Wood, C Aggarwal, DL Aisner… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …
management for NSCLC. These NCCN Guidelines Insights focus on recent updates in …
[HTML][HTML] MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate
Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …
[HTML][HTML] Emerging therapeutic agents for advanced non-small cell lung cancer
R Chen, R Manochakian, L James, AG Azzouqa… - Journal of hematology & …, 2020 - Springer
Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with
a poor prognosis and no known cure. Survival time is often short because of limited …
a poor prognosis and no known cure. Survival time is often short because of limited …
[HTML][HTML] Integrated Analysis of lncRNA–Mediated ceRNA Network in lung adenocarcinoma
X Wu, Z Sui, H Zhang, Y Wang, Z Yu - Frontiers in oncology, 2020 - frontiersin.org
Background A growing body of evidence indicates that long non-coding RNAs (lncRNAs)
can act as competitive endogenous RNAs (ceRNAs) to bind to microRNAs (miRNAs) …
can act as competitive endogenous RNAs (ceRNAs) to bind to microRNAs (miRNAs) …
Association between smoking history and tumor mutation burden in advanced non–small cell lung cancer
Lung carcinogenesis is a complex and stepwise process involving accumulation of genetic
mutations in signaling and oncogenic pathways via interactions with environmental factors …
mutations in signaling and oncogenic pathways via interactions with environmental factors …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …